UA77999C2 - Thymosin-alpha 1 for treatment of malignant glioblastoma - Google Patents

Thymosin-alpha 1 for treatment of malignant glioblastoma Download PDF

Info

Publication number: UA77999C2
Authority: UA; Ukraine
Prior art keywords: cells; thymalfazin; tumor; treated; glioblastoma
Prior art date: 2001-12-10

Application number

UA20040705523A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-10

Filing date

2002-10-12

Publication date

2007-02-15

2002-10-12 Application filed filed Critical

2007-02-15 Publication of UA77999C2 publication Critical patent/UA77999C2/uk

Links

208000005017 glioblastoma Diseases 0.000 title claims abstract description 45
238000011282 treatment Methods 0.000 title claims abstract description 33
230000003211 malignant effect Effects 0.000 title abstract description 6
108010078233 Thymalfasin Proteins 0.000 title 1
102400000800 Thymosin alpha-1 Human genes 0.000 title 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title 1
229960004231 thymalfasin Drugs 0.000 title 1
230000037396 body weight Effects 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 claims description 5
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract description 6
239000002671 adjuvant Substances 0.000 abstract description 4
229960005243 carmustine Drugs 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 97
206010028980 Neoplasm Diseases 0.000 description 42
241000700159 Rattus Species 0.000 description 27
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 26
230000001404 mediated effect Effects 0.000 description 17
230000001965 increasing effect Effects 0.000 description 16
210000004881 tumor cell Anatomy 0.000 description 16
102000001398 Granzyme Human genes 0.000 description 15
108060005986 Granzyme Proteins 0.000 description 15
230000000694 effects Effects 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 13
230000030833 cell death Effects 0.000 description 10
230000006907 apoptotic process Effects 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
230000036542 oxidative stress Effects 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
238000003556 assay Methods 0.000 description 8
231100000433 cytotoxic Toxicity 0.000 description 8
230000001472 cytotoxic effect Effects 0.000 description 8
230000000861 pro-apoptotic effect Effects 0.000 description 8
230000035899 viability Effects 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 7
230000034994 death Effects 0.000 description 7
231100000517 death Toxicity 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000004898 mitochondrial function Effects 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
108010046075 Thymosin Proteins 0.000 description 6
102000007501 Thymosin Human genes 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000000945 filler Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 5
230000003833 cell viability Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
210000004969 inflammatory cell Anatomy 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
206010018338 Glioma Diseases 0.000 description 3
208000007660 Residual Neoplasm Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
210000003618 cortical neuron Anatomy 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
210000001652 frontal lobe Anatomy 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000011532 immunohistochemical staining Methods 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
230000007115 recruitment Effects 0.000 description 3
230000008961 swelling Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
DEXCPFCZASYXPS-UHFFFAOYSA-N 1-chloro-1-nitrosourea Chemical compound NC(=O)N(Cl)N=O DEXCPFCZASYXPS-UHFFFAOYSA-N 0.000 description 2
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 2
108050006400 Cyclin Proteins 0.000 description 2
101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 2
208000002403 Encephalocele Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010019909 Hernia Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
231100000002 MTT assay Toxicity 0.000 description 2
238000000134 MTT assay Methods 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
210000000576 arachnoid Anatomy 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
208000006752 brain edema Diseases 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000011254 conventional chemotherapy Methods 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
230000002584 immunomodulator Effects 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
238000005497 microtitration Methods 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229930192851 perforin Natural products 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000002271 resection Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
QYUPYXHDDLXBET-UHFFFAOYSA-N 5-methyl-2,4-dioxopyrimidine-1-carbaldehyde Chemical compound CC1=CN(C=O)C(=O)NC1=O QYUPYXHDDLXBET-UHFFFAOYSA-N 0.000 description 1
231100000582 ATP assay Toxicity 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100492787 Caenorhabditis elegans mai-1 gene Proteins 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
208000032862 Clinical Deterioration Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010053172 Fatal outcomes Diseases 0.000 description 1
206010061431 Glial scar Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018341 Gliosis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
101100227721 Rattus norvegicus Frk gene Proteins 0.000 description 1
241000181331 Saron Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000011366 aggressive therapy Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
238000004820 blood count Methods 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960001480 chlorozotocin Drugs 0.000 description 1
239000011436 cob Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
210000002165 glioblast Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
201000003911 head and neck carcinoma Diseases 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
206010019465 hemiparesis Diseases 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
238000007489 histopathology method Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008102 immune modulation Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000032832 immune response to tumor cell Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000007422 luminescence assay Methods 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000002406 microsurgery Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000004065 mitochondrial dysfunction Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
229960001420 nimustine Drugs 0.000 description 1
VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000012797 qualification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
229960002185 ranimustine Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
108010075210 streptolysin O Proteins 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
108700016958 thymosin fraction 5 Proteins 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Prostheses (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA20040705523A 2001-12-10 2002-10-12 Thymosin-alpha 1 for treatment of malignant glioblastoma UA77999C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33714901P	2001-12-10	2001-12-10
PCT/US2002/039329 WO2003049697A2 (en)	2001-12-10	2002-12-10	Treatment of glioblastoma with thymosin-alpha 1

Publications (1)

Publication Number	Publication Date
UA77999C2 true UA77999C2 (en)	2007-02-15

Family

ID=23319320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040705523A UA77999C2 (en)	2001-12-10	2002-10-12	Thymosin-alpha 1 for treatment of malignant glioblastoma

Country Status (22)

Country	Link
US (1)	US20060166870A1 (de)
EP (1)	EP1461063B1 (de)
JP (1)	JP2005516910A (de)
KR (2)	KR20040091611A (de)
CN (1)	CN1615147A (de)
AT (1)	ATE356628T1 (de)
AU (1)	AU2002357115B2 (de)
BR (1)	BR0214848A (de)
CA (1)	CA2469595A1 (de)
DE (1)	DE60218896T2 (de)
DK (1)	DK1461063T3 (de)
EA (1)	EA005822B1 (de)
ES (1)	ES2283653T3 (de)
IL (1)	IL162434A0 (de)
MX (1)	MXPA04005585A (de)
NO (1)	NO20042927L (de)
NZ (1)	NZ533942A (de)
PL (1)	PL370829A1 (de)
PT (1)	PT1461063E (de)
SI (1)	SI1461063T1 (de)
UA (1)	UA77999C2 (de)
WO (1)	WO2003049697A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2288118B1 (es)	2006-05-10	2008-11-01	Bcn Peptides, S.A.	Procedimiento para sintetizar timosinas.
CN108226016A (zh) *	2018-01-12	2018-06-29	浙江普罗亭健康科技有限公司	肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒
CN112147326B (zh) *	2020-09-04	2022-04-08	北京大学	一种肿瘤免疫细胞亚群分型精准检测试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148786A (en) *	1978-06-26	1979-04-10	American Home Products Corporation	Analgesic polypeptide
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
IT1238231B (it) *	1989-12-18	1993-07-12	Consiglio Nazionale Ricerche	Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
FR2793684B1 (fr) *	1999-05-17	2001-08-10	Ethypharm Lab Prod Ethiques	Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6462017B1 (en) *	2000-05-01	2002-10-08	Sciclone Pharmaceuticals, Inc.	Method of reducing side effects of chemotherapy in cancer patients

2002
- 2002-10-12 UA UA20040705523A patent/UA77999C2/uk unknown
- 2002-12-10 NZ NZ533942A patent/NZ533942A/en unknown
- 2002-12-10 ES ES02804755T patent/ES2283653T3/es not_active Expired - Lifetime
- 2002-12-10 AT AT02804755T patent/ATE356628T1/de active
- 2002-12-10 IL IL16243402A patent/IL162434A0/xx unknown
- 2002-12-10 EA EA200400755A patent/EA005822B1/ru not_active IP Right Cessation
- 2002-12-10 CA CA002469595A patent/CA2469595A1/en not_active Abandoned
- 2002-12-10 AU AU2002357115A patent/AU2002357115B2/en not_active Ceased
- 2002-12-10 EP EP02804755A patent/EP1461063B1/de not_active Expired - Lifetime
- 2002-12-10 DK DK02804755T patent/DK1461063T3/da active
- 2002-12-10 BR BR0214848-0A patent/BR0214848A/pt not_active IP Right Cessation
- 2002-12-10 KR KR10-2004-7008939A patent/KR20040091611A/ko not_active Ceased
- 2002-12-10 PT PT02804755T patent/PT1461063E/pt unknown
- 2002-12-10 JP JP2003550748A patent/JP2005516910A/ja active Pending
- 2002-12-10 KR KR1020107002516A patent/KR20100029844A/ko not_active Ceased
- 2002-12-10 MX MXPA04005585A patent/MXPA04005585A/es active IP Right Grant
- 2002-12-10 DE DE60218896T patent/DE60218896T2/de not_active Expired - Lifetime
- 2002-12-10 PL PL02370829A patent/PL370829A1/xx not_active Application Discontinuation
- 2002-12-10 WO PCT/US2002/039329 patent/WO2003049697A2/en not_active Ceased
- 2002-12-10 US US10/498,050 patent/US20060166870A1/en not_active Abandoned
- 2002-12-10 SI SI200230509T patent/SI1461063T1/sl unknown
- 2002-12-10 CN CNA028270819A patent/CN1615147A/zh active Pending
2004
- 2004-07-08 NO NO20042927A patent/NO20042927L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1461063B1 (de)	2007-03-14
DE60218896T2 (de)	2007-09-20
WO2003049697A2 (en)	2003-06-19
NO20042927L (no)	2004-09-09
ATE356628T1 (de)	2007-04-15
PT1461063E (pt)	2007-06-18
EA200400755A1 (ru)	2004-12-30
WO2003049697A3 (en)	2004-01-15
NZ533942A (en)	2007-01-26
ES2283653T3 (es)	2007-11-01
CN1615147A (zh)	2005-05-11
AU2002357115A1 (en)	2003-06-23
BR0214848A (pt)	2004-11-09
JP2005516910A (ja)	2005-06-09
EP1461063A2 (de)	2004-09-29
MXPA04005585A (es)	2005-03-23
CA2469595A1 (en)	2003-06-19
EP1461063A4 (de)	2005-08-31
DK1461063T3 (da)	2007-05-21
IL162434A0 (en)	2005-11-20
PL370829A1 (en)	2005-05-30
EA005822B1 (ru)	2005-06-30
KR20040091611A (ko)	2004-10-28
AU2002357115B2 (en)	2007-12-13
DE60218896D1 (de)	2007-04-26
KR20100029844A (ko)	2010-03-17
US20060166870A1 (en)	2006-07-27
SI1461063T1 (sl)	2007-08-31

Publication	Publication Date	Title
US5639757A (en)	1997-06-17	4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
Fairweather et al.	1999	Mechanisms of fasciolicide action and drug resistance in Fasciola hepatica
US20020028779A1 (en)	2002-03-07	Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
KR20080096716A (ko)	2008-10-31	세포 사멸을 조절하는 세포독성인자
KR20130142164A (ko)	2013-12-27	암 치료 및 면역억제를 위한 시로신고핀과 미토콘드리아 억제제의 조합물
EP0731697B1 (de)	2001-04-18	Ssi tyrphostine und pharmazeutische zusammensetzungen
CA2083945C (en)	1995-02-07	An antiviral composition
KR20010033150A (ko)	2001-04-25	항종양제용 다촉매 프로테아제 억제제
UA77999C2 (en)	2007-02-15	Thymosin-alpha 1 for treatment of malignant glioblastoma
US9422224B2 (en)	2016-08-23	Methods of treatment using a BCAT1 inhibitor
Buzzi et al.	1973	Inhibition of growth of Ehrlich tumors in Swiss mice by diphtheria toxin
Aubertin et al.	1977	Solubilised viral proteins produce fatal hepatitis in mice
Mukerjee et al.	1996	Dengue virus‐induced cytotoxin releases nitrite by spleen cells
KR19990087673A (ko)	1999-12-27	바이러스 감염증 예방 치료제
CN1245720A (zh)	2000-03-01	含有钙调神经磷酸酶b亚基的药物组合物
CN109575108A (zh)	2019-04-05	以ptp1b为靶点的新型bh3模拟肽化合物及其制备方法和应用
CN112076189B (zh)	2021-11-12	一种酰胺化合物在制备治疗脓毒症药物中的应用
US20110015186A1 (en)	2011-01-20	Methods and compositions for protecting and treating neuroinjury
CN116459247B (zh)	2026-03-03	Necrostatin-1在制备预防和/或治疗急性马兜铃酸肾病药物中的应用
CN101766621A (zh)	2010-07-07	Morphine在制备治疗帕金森病的药物中的应用
EP1549742B1 (de)	2014-01-08	Verfahren zur selektion von das klonzellwachstum hemmenden verbindungen sowie verwendung davon
RU2207127C1 (ru)	2003-06-27	Способ лечения экспериментального туберкулеза
WO1995020650A1 (en)	1995-08-03	Strain of trichoderma harzianum rifai, process for obtaining l-lysine-alpha-oxidase as an inhibitor of viral and bacterial activity, immunomodulator and skin healing agent
KR20230122367A (ko)	2023-08-22	항암 활성을 가지는 폴리포루스 울릉구스 균주
Ramya et al.	2017	Effect of anti-inflammatory activity of Hellenia speciosa (L.) and Costus pictus (L.)